Results 111 to 120 of about 5,638,503 (214)

Genomics‐led approach to drug testing in models of undifferentiated pleomorphic sarcoma

Molecular Oncology, EarlyView.
GA text Genomic data from undifferentiated pleomorphic sarcoma patients and preclinical models were used to inform a targeted drug screen. Selected compounds were tested in 2D and 3D cultures of UPS cell lines. A combination of trametinib and infigratinib was synergistic in the majority of UPS cell lines tested, which was further confirmed in an ex ...
Piotr J. Manasterski, Molly R. Danks, John P. Thomson, Morwenna Muir, Martin Lee, John C. Dawson, Ana T. Amaral, Juan Diaz‐Martin, David S. Moura, Javier Martin‐Broto, Ali Alsaadi, Donald M. Salter, Ailsa J. Oswald, Graeme Grimes, Larry Hayward, Ted R. Hupp, Karen Sisley, Paul H. Huang, Neil O. Carragher, Valerie G. Brunton   +19 more
wiley   +1 more source

<i>Rotavirus alphagastroenteritidis</i>: Circulating Strains After the Introduction of the Rotavirus Vaccine (Rotarix^®) in Luanda Province of Angola. [PDF]

Viruses
Vita DG, Santiso-Bellón C, Lemos M, Neto Z, Fortes-Gabriel E, Brito M, Sebastião CS, Rodriguez-Diaz J, Cunha C, Istrate C.   +9 more
europepmc   +1 more source

Улога на метаболичниот Ñиндром во развој и прогреÑија на хроничната бубрежна ÑлабоÑÑ‚

, 2015
Tatjana Barjaktarova Prosheva, Лилјана Тозија   +1 more
openalex  

Ð Ð¾Ð²Ð¸Ñ Ñ‚ Международен Ñ Ñ‚Ð°Ð½Ð´Ð°Ñ€Ñ‚ за Ñ„Ð¸Ð½Ð°Ð½Ñ Ð¾Ð²Ð¾ отчитане 17 и Ð¿Ñ€ÐµÐ´Ð¸Ð·Ð²Ð¸ÐºÐ°Ñ‚ÐµÐ»Ñ Ñ‚Ð²Ð°Ñ‚Ð° пред Ð·Ð°Ñ Ñ‚Ñ€Ð°Ñ…Ð¾Ð²Ð°Ñ‚ÐµÐ»Ð½Ð¸Ñ‚Ðµ компании [PDF]

, 2020
Ð Ð ÐμÐ ⁄ Ð ⁄ Ð ⁄ ра СтаР⁄ чÐμРа-ТР⁄ Ð ́Ð ⁄ рР⁄ Ра, РаР́Ñ Ð’ÐμÐ Ð ̧Ð ⁄ Ð ⁄ Ра-СР⁄ ÐoÐ ⁄ Ð Ð ⁄ Ра   +1 more
openalex  

The subcellular distribution of phosphorylated Y‐box‐binding protein‐1 at S102 in colorectal cancer patients, stratified by KRAS mutational status and clinicopathological features

Molecular Oncology, EarlyView.
This study identifies nuclear YB‐1 S102 phosphorylation as a marker associated with KRAS and FBXW7 mutations in colorectal cancer. Mutated KRAS correlates specifically with nuclear, not cytoplasmic, S102 YB‐1. These findings provide the first ex vivo evidence of this link in CRC and suggest future studies should assess the prognostic and therapeutic ...
Konstanze Lettau, Stephan Forchhammer, Birgit Fehrenbacher, Lejla Mahmutovic, Marcus Scharpf, Gunnar Blumenstock, Martin Schaller, Irina Bonzheim, Shayan Khozooei, Mahmoud Toulany   +9 more
wiley   +1 more source

Treatment of Hypovitaminosis D With Cholecalciferol in Dogs With Protein-Losing Enteropathies: A Randomized, Double-Blind, Placebo-Controlled, Clinical Trial. [PDF]

J Vet Intern Med
Jablonski SA, Shropshire SB, Watson VE, Manchester AC, Cridge H, Lennon EM, Tolbert MK.   +6 more
europepmc   +1 more source

A nucleotide‐independent, pan‐RAS‐targeted DARPin elicits anti‐tumor activity in a multimodal manner

Molecular Oncology, EarlyView.
We report a Designed Ankyrin Repeat Protein that binds and inhibits RAS proteins, which serve as central cell signaling hubs and are essential for the progression of many cancers. Its unique feature is that it does not discriminate between different RAS isoforms or mutations and is capable of binding to RAS in both its active (GTP‐bound) and inactive ...
Jonas N. Kapp, Wouter P. R. Verdurmen, Jonas V. Schaefer, Kari Kopra, Gabriela Nagy‐Davidescu, Elodie Richard, Marie‐Julie Nokin, Patrick Ernst, Rastislav Tamaskovic, Martin Schwill, Ralph Degen, Claudia Scholl, David Santamaria, Andreas Plückthun   +13 more
wiley   +1 more source

LymphSens study: the enigma of subjective lymphoedema - how often and why do patients report lymphoedema after breast cancer treatment without an objective measurable swelling? The role of lymphatic and sensory processing problems: a protocol for a multicentre prospective longitudinal study. [PDF]

BMJ Open
Gursen C, Meeus M, Verbeelen K, Vets N, Spincemaille L, Smeets A, Thomis S, Fieuws S, Vanderheyden H, Gebruers N, Tjalma W, Johansson K, Keeley V, De Groef A, Devoogdt N.   +14 more
europepmc   +1 more source

Therapeutic applications of a novel humanized monoclonal antibody targeting chemokine receptor CCR9 in pancreatic cancer

Molecular Oncology, EarlyView.
C–C chemokine receptor type 9 (CCR9) is an immune checkpoint in pancreatic ductal adenocarcinoma (PDAC). Novel anti‐CCR9 antibody SRB2 was evaluated in combination with cytotoxic chemotherapy in PDAC cells, patient‐derived organoids, patient‐derived xenografts, and humanized mouse models.
Hannah G. McDonald, Anna M. Reagan, Charles J. Bailey, Mei Gao, Muqiang Gao, Angelica L. Solomon, Michael J. Cavnar, Prakash K. Pandalai, Mautin T. Barry‐Hundeyin, Megan M. Harper, Justin A. Rueckert, Ángela Turrero, Araceli Tobio, Anxo Vidal, Daniel Roca‐Lema, Elia Álvarez‐Coiradas, Pablo Garrido, Laureano Simón, Joseph Kim   +18 more
wiley   +1 more source

Association of meal component combinations with nutrient adequacy in Japanese adults. [PDF]

Asia Pac J Clin Nutr
Murahata H, Nakamura K, Imai E.
europepmc   +1 more source